<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990596</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_9831_CEPAGE</org_study_id>
    <nct_id>NCT04990596</nct_id>
  </id_info>
  <brief_title>Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)</brief_title>
  <acronym>CEPAGE</acronym>
  <official_title>Mechanisms fo Clopidogrel Resistance in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clopidogrel resistance rate of 40-50% has been found in the population over 70 years of&#xD;
      age, whereas biological resistance, associated with an increased risk of cardiovascular&#xD;
      events, is observed in about 20-30% of younger patients. One hypothesis is that the active&#xD;
      metabolite is less available in resistant patients. Indeed, 85% of the absorbed clopidogrel&#xD;
      undergoes inactivation by esterases. Then the remaining fraction undergoes two steps of&#xD;
      metabolisation to the active thiol metabolite by CYP450, essentially the isoform 2C19. In&#xD;
      older adults, increased esterase activity and/or decreased CYP450 2C19 activity may lead to a&#xD;
      decreased concentration of the active metabolite. Multiple chronic conditions and&#xD;
      polypharmacy encountered in older individuals are associated with basal platelet&#xD;
      hyperactivity, and may also contribute to a poor response to clopidogrel. No data on the&#xD;
      relationship between platelet response and circulating metabolite levels, or on the&#xD;
      determinants of response to clopidogrel, are currently available in the geriatric population.&#xD;
      Therefore, we propose to analyse the relationship between age and platelet and extra-platelet&#xD;
      mechanisms potentially involved in the variability of response to clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective observational multi-centre study. The main objective is assessing&#xD;
      the pharmacokinetics (PK) and pharmacodynamics (PD) correlation of clopidogrel action in&#xD;
      older adults, i.e. correlation between clopidogrel active metabolite concentration (PK) and&#xD;
      platelet response phenotype (PD). The primary outcome is the correlation between the&#xD;
      concentration of active metabolite of clopidogrel (PK) over the percentage of maximum&#xD;
      aggregation at 10 μM ADP (PD) as a function of age. Inclusion criteria are: age 50-100 years&#xD;
      old, hospitalization in one of the 4 participating centres, treatment with clopidogrel 75&#xD;
      milligrammes per day, for at least 10 days. The statistical analysis is a multiple linear&#xD;
      regression model with the introduction of an interaction term. The first variable of interest&#xD;
      (explanatory) is the concentration of the metabolite. A linear regression model will be used&#xD;
      to estimate the proportion of variance explained. The analyses will be conducted with SAS&#xD;
      version 9.4 (SAS Institute Inc., Cary, N.C., USA). Results will be published in an&#xD;
      international scientific review.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">July 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PK/PD correlation - clopidogrel active metabolite concentration (pharmacokinetics PK in ) / platelet response phenotype(pharmacodynamics, PD)</measure>
    <time_frame>Day 0</time_frame>
    <description>Correlation PK (concentration of active metabolite of clopidogrel) / PD (%maximum aggregation at 10 μM ADP) as a function of age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of prodrug/active metabolite concentrations</measure>
    <time_frame>Day 0</time_frame>
    <description>Ratio of prodrug/active metabolite concentrations as a function of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the area under the curve of aggregationat 10 μM ADP and the concentration of the active metabolite of clopidogrel</measure>
    <time_frame>Day 0</time_frame>
    <description>Correlation between the area under the curve of aggregation at 10μM ADP and the concentration of the active metabolite of clopidogrelas a function of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the Platelet Reactivity Index of VASPphosphorylation and the concentration of the active metabolite of clopidogrel</measure>
    <time_frame>Day 0</time_frame>
    <description>Correlation between the Platelet Reactivity Index of VASP phosphorylation and the concentration of the active metabolite of clopidogrel in relation to age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of factors influencing PK/PD response</measure>
    <time_frame>Day 0</time_frame>
    <description>clinical data: gender</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of factors influencing PK/PD response</measure>
    <time_frame>Day 0</time_frame>
    <description>clinical data: body mass index in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of factors influencing PK/PD response</measure>
    <time_frame>Day 0</time_frame>
    <description>clinical data: Cumulative Illness Rating Scale-Geriatric</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Drug Resistance</condition>
  <arm_group>
    <arm_group_label>Age Group 50 to 59</arm_group_label>
    <description>Inclusion criteria :&#xD;
age 50-100 years old,&#xD;
hospitalization in one of the participating centres,&#xD;
treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.&#xD;
Non-inclusion criteria :&#xD;
treatment with another antithrombotic drug,&#xD;
myeloproliferative syndrome,&#xD;
platelet count &lt; 100 gigas/liter,&#xD;
acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,&#xD;
dialysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age Group 60 to 69</arm_group_label>
    <description>Inclusion criteria :&#xD;
age 50-100 years old,&#xD;
hospitalization in one of the participating centres,&#xD;
treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.&#xD;
Non-inclusion criteria :&#xD;
treatment with another antithrombotic drug,&#xD;
myeloproliferative syndrome,&#xD;
platelet count &lt; 100 gigas/liter,&#xD;
acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,&#xD;
dialysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age Group 70 to 79</arm_group_label>
    <description>Inclusion criteria :&#xD;
age 50-100 years old,&#xD;
hospitalization in one of the participating centres,&#xD;
treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.&#xD;
Non-inclusion criteria :&#xD;
treatment with another antithrombotic drug,&#xD;
myeloproliferative syndrome,&#xD;
platelet count &lt; 100 gigas/liter,&#xD;
acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,&#xD;
dialysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age Group 80 to 89</arm_group_label>
    <description>Inclusion criteria :&#xD;
age 50-100 years old,&#xD;
hospitalization in one of the participating centres,&#xD;
treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.&#xD;
Non-inclusion criteria :&#xD;
treatment with another antithrombotic drug,&#xD;
myeloproliferative syndrome,&#xD;
platelet count &lt; 100 gigas/liter,&#xD;
acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,&#xD;
dialysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age Group 90 to 100</arm_group_label>
    <description>Inclusion criteria :&#xD;
age 50-100 years old,&#xD;
hospitalization in one of the participating centres,&#xD;
treatment with clopidogrel 75 milligrammes per day, for at least 10 days, for primary or secondary prevention of cardiovascular events.&#xD;
Non-inclusion criteria :&#xD;
treatment with another antithrombotic drug,&#xD;
myeloproliferative syndrome,&#xD;
platelet count &lt; 100 gigas/liter,&#xD;
acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,&#xD;
dialysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>additional blood sample</intervention_name>
    <description>One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.</description>
    <arm_group_label>Age Group 50 to 59</arm_group_label>
    <arm_group_label>Age Group 60 to 69</arm_group_label>
    <arm_group_label>Age Group 70 to 79</arm_group_label>
    <arm_group_label>Age Group 80 to 89</arm_group_label>
    <arm_group_label>Age Group 90 to 100</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Centralized determination of clopidogrel and active metabolite (pharmacology Samples)&#xD;
      Centralized determination of plasma markers of platelet activation (hematology Samples)&#xD;
      Centralized study of genetic polymorphisms (pharmacology Samples)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients from 50 to 100 years treated with clopidogrel 75 mg/d for at least 10 days for&#xD;
        primary or secondary prevention of cardiovascular events&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Consecutive patients per 10-year age range, (20 patients per age range from 50 to 100 years&#xD;
        included) :&#xD;
&#xD;
          -  hospitalization in one of the participating centres,&#xD;
&#xD;
          -  treatment with clopidogrel 75 mg/d for at least 10 days for primary or secondary&#xD;
             prevention of cardiovascular events.&#xD;
&#xD;
          -  who have received the information and have not expressed their opposition to&#xD;
             participate in the study and who have given their written consent for the performance&#xD;
             of genetic examinations and the realization of a biocollection&#xD;
&#xD;
          -  affiliated to French social security system&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  treatment with another antithrombotic agent,&#xD;
&#xD;
          -  myeloproliferative syndrome,&#xD;
&#xD;
          -  platelet count &lt; 100 G/L,&#xD;
&#xD;
          -  acute inflammatory situation: severe sepsis, documented acute infection, chronic&#xD;
             systemic inflammatory disease or active cancer,&#xD;
&#xD;
          -  under dialysis,&#xD;
&#xD;
          -  no participation in another clinical study,&#xD;
&#xD;
          -  deprived of liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique SOMME, MD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Rennes - Service de Gériatrie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle GOUIN-THIBAULT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Rennes - Service d'Hématologie Biologique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric PAUTAS, MD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Charles Foix - Court séjour Gériatrique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corinne FRERE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Pitié-Salpêtrière - Hématologie Biologique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena PAILLAUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou, Service de Gériatrie Aiguë,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascale GAUSSEM, MD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou - Service d'Hématologie Biologique,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Guillaume DILLINGER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Lariboisière - Service de Cardiologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Virginie SIGURET, MD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Lariboisière - Hématologie Biologique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joaquim PRUD'HOMM, MD</last_name>
    <phone>2 99 28 41 10</phone>
    <phone_ext>+33</phone_ext>
    <email>joaquim.prud'homm@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle GOUIN-THIBAULT, MD, PhD</last_name>
    <phone>2 99 28 95 63</phone>
    <phone_ext>+33</phone_ext>
    <email>isabelle.gouin@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Charles Foix</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric PAUTAS, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou,</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena PAILLAUD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Guillaume DILLINGER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique SOMME, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>primary or secondary prevention of cardiovascular events</keyword>
  <keyword>older adults</keyword>
  <keyword>clopidogrel resistance</keyword>
  <keyword>Drug resistance</keyword>
  <keyword>Antiplatelet resistance</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

